---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-091629"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2026-08-06T11:15:15+00:00"
generated_at: "2026-08-06T11:20:29.059753+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aclaris Therapeutics Q2 2026 net loss $21.5M; cash $170.6M; ATI-052 data supports quarterly dosing

## Summary
- Net loss $21.5M in Q2 2026 vs $15.4M in Q2 2025; revenue $1.6M vs $1.8M.
- Cash, equivalents and marketable securities $170.6M at June 30, 2026; subsequent ATM raised $40.2M gross from 7.3M shares.
- Phase 1a SAD/MAD data for ATI-052 (anti-TSLP/IL-4Rα bispecific) shows favorable safety and potential for quarterly dosing.
- Top line results expected H2 2026 from Phase 1b POC trials of ATI-052 in asthma and atopic dermatitis, and Phase 2 trial of bosakitug in AD.
- Plan to initiate Phase 2b program for ATI-052 and Phase 2b trial of modzatinib in lichen planus in Q4 2026.

## SEC filing metadata
- accession: 0001104659-26-091629
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2026-08-06T11:15:15+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000110465926091629/0001104659-26-091629-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000110465926091629/acrs-20260806x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-091629
- JSON: https://secwatch.observer/filing/0001104659-26-091629.json
- Plain text: https://secwatch.observer/filing/0001104659-26-091629.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.